Lung Cancer Staging and Associated Genetic and Epigenetic Events |
Kim, Dohun
(Department of Thoracic and Cardiovascular Surgery, College of Medicine, Chungbuk National University and Chungbuk National University Hospital)
Lee, You-Soub (Department of Biochemistry, College of Medicine, Chungbuk National University) Kim, Duk-Hwan (Department of Molecular Cell Biology, Samsung Biomedical Research Institute, School of Medicine, Sungkyunkwan University) Bae, Suk-Chul (Department of Biochemistry, College of Medicine, Chungbuk National University) |
1 | Shepherd, F.A., Lacas, B., Le Teuff, G., Hainaut, P., Jänne, P.A., Pignon, J.P., Le Chevalier, T., Seymour, L., Douillard, J.Y., Graziano, S., et al. (2017). Pooled analysis of the prognostic and predictive effects of TP53 comutation status combined with KRAS or EGFR mutation in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy. J. Clin. Oncol. 35, 2018-2027. DOI |
2 | Travis, W.D., Asamura, H., Bankier, A.A., Beasley, M.B., Detterbeck, F., Flieder, D.B., Goo, J.M., MacMahon, H., Naidich, D., Nicholson, A.G., et al. (2016). The IASLC lung cancer staging project: proposals for coding T categories for subsolid nodules and assessment of tumor size in part-solid tumors in the forthcoming eighth edition of the TNM Classification of lung cancer. J. Thorac. Oncol. 11, 1204-1223. DOI |
3 | Tsai, T.H., Wu, S.G., Hsieh, M.S., Yu, C.J., Yang, J.C., and Shih, J.Y. (2015). Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion. Lung Cancer 88, 208-214. DOI |
4 | Vlahos, I. (2018). Dilemmas in lung cancer staging. Radiol. Clin. North Am. 56, 419-435. DOI |
5 | Wistuba, II., Behrens, C., Milchgrub, S., Bryant, D., Hung, J., Minna, J.D., and Gazdar, A.F. (1999). Sequential molecular abnormalities are involved in the multistage development of squamous cell lung carcinoma. Oncogene 21, 643-650. DOI |
6 | Yanagawa, N., Tamura, G., Oizumi, H., Kanauchi, N., Endoh, M., Sadahiro, M., and Motoyama, T. (2007). Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers. Lung Cancer 58, 131-138. DOI |
7 | Yatabe, Y., Borczuk, A.C., and Powell, C.A. (2014). Do all lung adenocarcinomas follow a stepwise progression? Lung Cancer 74, 7-11. DOI |
8 | American Joint Committee (1977). Manual for Staging of Cancer 1977 (Chicago: American Joint Committee). |
9 | Agathanggelou, A., Honorio, S., Macartney, D.P., Martinez, A., Dallol, A., Rader, J., Fullwood, P., Chauhan, A., Walker, R., Shaw, J.A., et al. (2001). Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene 20, 1509-1518. DOI |
10 | Ahrendt, S.A., Hu, Y., Buta, M., McDermott, M.P., Benoit, N., Yang, S.C., Wu, L., and Sidransky, D. (2003). p53 mutations and survival in stage I non-small-cell lung cancer: results of a prospective study. J. Natl. Cancer Inst. 95, 961-970. DOI |
11 | Asamura, H., Chansky, K., Crowley, J., Goldstraw, P., Rusch, V.W., Vansteenkiste, J.F., Watanabe, H., Wu, Y.L., Zielinski, M., Ball, D., et al. (2015). The International Association for the Study of Lung Cancer Lung Cancer Staging Project: proposals for the revision of the N descriptors in the forthcoming 8th edition of the TNM Classification for lung cancer. J. Thorac. Oncol. 10, 1675-1684. DOI |
12 | Belinsky, S.A. (2004). Gene-promoter hypermethylation as a biomarker in lung cancer. Nat. Rev. Cancer 4, 707-717. DOI |
13 | Belinsky, S.A. (2005). Silencing of genes by promoter hypermethylation: key event in rodent and human lung cancer. Carcinogenesis 26, 1481-1487. DOI |
14 | Birchmeier, C., Birchmeier, W., Gherardi, E., and Vande Woude, G.F. (2003). Met, metastasis, motility and more. Nat. Rev. Mol. Cell Biol. 4, 915-925. DOI |
15 | Duhig, E.E., Dettrick, A., Godbolt, D.B., Pauli, J., van Zwieten, A., Hansen, A.R., Yang, I.A., Fong, K.M., Clarke, B.E., and Bowman, R.V. (2015). Mitosis trumps T stage and proposed international association for the study of lung cancer/american thoracic society/european respiratory society classification for prognostic value in resected stage 1 lung adenocarcinoma. J. Thorac. Oncol. 10, 673-681. DOI |
16 | Yoo, S.B., Chung, J.H., Lee, H.J., Lee, C.T., Jheon, S., and Sung, S.W. (2010). Epidermal growth factor receptor mutation and p53 overexpression during the multistage progression of small adenocarcinoma of the lung. J. Thorac. Oncol. 5, 964-969. DOI |
17 | Cadranel, J., Mauguen, A., Faller, M., Zalcman, G., Buisine, M.P., Westeel, V., Longchampt, E., Wislez, M., Coudert, B., Daniel, C., et al. (2012). Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2). J. Thorac. Oncol. 7, 1490-1502. DOI |
18 | Cappuzzo, F., Marchetti, A., Skokan, M., Rossi, E., Gajapathy, S., Felicioni, L., Del Grammastro, M., Sciarrotta, M.G., Buttitta, F., Incarbone, M., et al. (2009). Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J. Clin. Oncol. 27, 1667-1674. DOI |
19 | Chen, X., Deng, Y., Shi, Y., Zhu, W., Cai, Y., Xu, C., Zhu, K., Zheng, X., Chen, G., Xie, Q., et al. (2018). Loss of expression rather than cytoplasmic mislocalization of RUNX3 predicts worse outcome in non-small cell lung cancer. Oncol. Lett. 15, 5043-5055. |
20 | Dubois, F., Keller, M., Calvayrac, O., Soncin, F., Hoa, L., Hergovich, A., Parrini, M.C., Mazieres, J., Vaisse-Lesteven, M., Camonis, J., et al. (2016). RASSF1A suppresses the invasion and metastatic potential of human non-small cell lung cancer cells by inhibiting YAP activation through the GEF-H1/RhoB pathway. Cancer Res. 76, 1627-1640. DOI |
21 | Goldstraw, P., Chansky, K., Crowley, J., Rami-Porta, R., Asamura, H., Eberhardt, W.E., Nicholson, A.G., Groome, P., Mitchell, A., and Bolejack, V. (2016). The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM Classification for lung cancer. J. Thorac. Oncol. 11, 39-51. DOI |
22 | Eberhardt, W.E., Mitchell, A., Crowley, J., Kondo, H., Kim, Y.T., Turrisi, A., 3rd., Goldstraw, P., and Rami-Porta, R. (2015). The IASLC lung cancer staging project: proposals for the revision of the M descriptors in the forthcoming eighth edition of the TNM Classification of lung cancer. J. Thorac. Oncol. 10, 1515-1522. DOI |
23 | Feldser, D.M., Kostova, K.K., Winslow, M.M., Taylor, S.E., Cashman, C., Whittaker, C.A., Sanchez-Rivera, F.J., Resnick, R., Bronson, R., Hemann, M.T., et al. (2010). Stage-specific sensitivity to p53 restoration during lung cancer progression. Nature 468, 572-575. DOI |
24 | Go, H., Jeon, Y.K., Park, H.J., Sung, S.W., Seo, J.W., and Chung, D.H. (2010). High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer. J. Thorac. Oncol. 5, 305-313. DOI |
25 | Ito, Y., Bae, S.C., and Chuang, L.S. (2015). The RUNX family: developmental regulators in cancer. Nat. Rev. Cancer 15, 81-95. DOI |
26 | Kobayashi, N., Toyooka, S., Soh, J., Ichimura, K., Yanai, H., Suehisa, H., Ichihara, S., Yamane, M., Aoe, M., Sano, Y., et al. (2007). Risk factors for recurrence and unfavorable prognosis in patients with stage I non-small cell lung cancer and a tumor diameter of 20 mm or less. J. Thorac. Oncol. 2, 808-812. DOI |
27 | Izumchenko, E., Chang, X., Brait, M., Fertig, E., Kagohara, L.T., Bedi, A., Marchionni, L., Agrawal, N., Ravi, R., Jones, S., et al. (2015). Targeted sequencing reveals clonal genetic changes in the progression of early lung neoplasms and paired circulating DNA. Nat. Commun. 16, 8258. |
28 | Jamal-Hanjani, M., Wilson, G.A., McGranahan, N., Birkbak, N.J., Watkins, T.B.K., Veeriah, S., Shafi, S., Johnson, D.H., Mitter, R., Rosenthal, R., et al. (2017). Tracking the evolution of non-small-cell lung cancer. N. Engl. J. Med. 376, 2109-2121. DOI |
29 | Janne, P.A., Yang, J.C., Kim, D.W., Planchard, D., Ohe, Y., Ramalingam, S.S., Ahn, M.J., Kim, S.W., Su, W.C., Horn, L., et al. (2015). AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N. Engl. J. Med. 372, 1689-1699. DOI |
30 | Jones, P.A. and Baylin, S.B. (2007). The epigenomics of cancer. Cell 128, 683-692. DOI |
31 | Kobayashi, S., Boggon, T.J., Dayaram, T., Jänne, P.A., Kocher, O., Meyerson, M., Johnson, B.E., Eck, M.J., Tenen, D.G., and Halmos, B. (2005). EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 352, 786-792. DOI |
32 | Kosaka, T., Yatabe, Y., Onozato, R., Kuwano, H., and Mitsudomi, T. (2009). Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma. J. Thorac. Oncol. 4, 22-29. DOI |
33 | Lee, J.W., Kim, D.M., Jang, J.W., Park, T.G., Song, S.H., Lee, Y.S., Chi, X.Z., Park, I.Y., Hyun, J.W., Ito, Y., et al. (2019). RUNX3 regulates cell cycle-dependent chromatin dynamics by functioning as a pioneer factor of the restriction-point. Nat. Commun. 10, 1897. DOI |
34 | Min, J.H., Lee, H.Y., Lee, K.S., Han, J., Park, K., Ahn, M.J., and Lee, S.J. (2010). Stepwise evolution from a focal pure pulmonary ground-glass opacity nodule into an invasive lung adenocarcinoma: an observation for more than 10 years. Lung Cancer 69, 123-126. DOI |
35 | Lee, K.S., Lee, Y.S., Lee, J.M., Ito, K., Cinghu, S., Kim, J.H., Jang, J.W., Li, Y.H., Goh, Y.M., Chi, X.Z., et al. (2010). Runx3 is required for the differentiation of lung epithelial cells and suppression of lung cancer. Oncogene 29, 3349-3361. DOI |
36 | Lee, Y.S. and Bae, S.C. (2016). How do K-RAS-activated cells evade cellular defense mechanisms? Oncogene 35, 827-832. DOI |
37 | Lee, Y.S., Lee, J.W., Jang, J.W., Chi, X.Z., Kim, J.H., Li, Y.H., Kim, M.K., Kim, D.M., Choi, B.S., Kim, E.G., et al. (2013). Runx3 inactivation is a crucial early event in the development of lung adenocarcinoma. Cancer Cell 24, 603-616. DOI |
38 | Matsumoto, S., Iwakawa, R., Kohno, T., Suzuki, K., Matsuno, Y., Yamamoto, S., Noguchi, M., Shimizu, E., and Yokota, J. (2006). Frequent EGFR mutations in noninvasive bronchioloalveolar carcinoma. Int. J. Cancer 118, 2498-2504. DOI |
39 | McEvoy, S.H., Halpenny, D.F., Viteri-Jusue, A., Hayes, S.A., Plodkowski, A.J., Riely, G.J., and Ginsberg, M.S. (2017). Investigation of patterns of nodal metastases in BRAF mutant lung cancer. Lung Cancer 108, 62-65. DOI |
40 | Nakanishi, H., Matsumoto, S., Iwakawa, R., Kohno, T., Suzuki, K., Tsuta, K., Matsuno, Y., Noguchi, M., Shimizu, E., Yokota, J. (2009). Whole genome comparison of allelic imbalance between noninvasive and invasive small-sized lung adenocarcinomas. Cancer Res. 69, 1615-1623. DOI |
41 | Rami-Porta, R., Bolejack, V., Giroux, D.J., Chansky, K., Crowley, J., Asamura, H., and Goldstraw, P. (2014). The IASLC lung cancer staging project: the new database to inform the eighth edition of the TNM Classification of lung cancer. J. Thorac. Oncol. 9, 1618-1624. DOI |
42 | Noguchi, M. (2010). Stepwise progression of pulmonary adenocarcinoma: clinical and molecular implications. Cancer Metastasis Rev. 29, 15-21. DOI |
43 | Omar, M.F., Ito, K., Nga, M.E., Soo, R., Peh, B.K., Ismail, T.M., Thakkar, B., Soong, R., Ito, Y., and Salto-Tellez, M. (2012). RUNX3 downregulation in human lung adenocarcinoma is independent of p53, EGFR or KRAS status. Pathol. Oncol. Res. 18, 783-792. DOI |
44 | Pulling, L.C., Divine, K.K., Klinge, D.M., Gilliland, F.D., Kang, T., Schwartz, A.G., Bocklage, T.J., and Belinsky, S.A. (2003). Promoter hypermethylation of the O6-methylguanine-DNA methyltransferase gene: more common in lung adenocarcinomas from never-smokers than smokers and associated with tumor progression. Cancer Res. 63, 4842-4848. |
45 | Pulling, L.C., Vuillemenot, B.R., Hutt, J.A., Devereux, T.R., and Belinsky, S.A. (2004). Aberrant promoter hypermethylation of the death-associated protein kinase gene is early and frequent in murine lung tumors induced by cigarette smoke and tobacco carcinogens. Cancer Res. 64, 3844-3848. DOI |
46 | Rami-Porta, R. (2016). IASLC Staging Manual in Thoracic Oncology, 2nd Edition (North Fort Myers: Editorial Rx Press). |
47 | Riquet, M., Le Pimpec-Barthes, F., and Danel, C. (1998). Axillary lymph node metastases from bronchogenic carcinoma. Ann. Thorac. Surg. 66, 920-922. DOI |
48 | Sequist, L.V., Yang, J.C., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., Geater, S.L., Orlov, S., Tsai, C.M., Boyer, M., et al. (2013). Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J. Clin. Oncol. 31, 3327-3334. DOI |
49 | Satoh, H., Ishikawa, H., Kagohashi, K., Kurishima, K., and Sekizawa, K. (2009). Axillary lymph node metastasis in lung cancer. Med. Oncol. 26, 147-150. DOI |